M

Mersana Therapeutics
D

MRSN

0.53480
USD
-0.00
(-0.13%)
مغلق
حجم التداول
60,862
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
66,065,400
أصول ذات صلة
    ABBV
    ABBV
    1.200
    (0.60%)
    202.140 USD
    AMGN
    AMGN
    5.10
    (1.71%)
    303.15 USD
    AZN
    AZN
    -0.350
    (-0.47%)
    74.220 USD
    BMY
    BMY
    0.050
    (0.09%)
    55.840 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    GSK
    GSK
    -0.320
    (-0.87%)
    36.650 USD
    LLY
    LLY
    0.67
    (0.08%)
    874.04 USD
    MRK
    MRK
    1.820
    (2.08%)
    89.500 USD
    PFE
    PFE
    0.405
    (1.56%)
    26.305 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    SYK
    SYK
    -3.72
    (-0.96%)
    382.74 USD
    المزيد
الأخبار المقالات

العنوان: Mersana Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.